Radiation plus targeted immunotherapy for liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with liver cancer (HCC) that cannot be treated with surgery or ablation.
- Your liver cancer is at an intermediate stage (CNLC Ib-IIIa, without major vein invasion).
- You have at least one measurable tumor on imaging.
- You have not had prior systemic treatments (targeted therapy, immunotherapy, chemotherapy) for liver cancer.
- Your liver function is good (Child-Pugh A or B with ≤7 points) and you are in generally good health (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
This study tests whether combining radiation therapy with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—can shrink liver cancer that has spread into the main portal vein. It’s for people with advanced liver cancer who haven’t had any systemic treatment before.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
This trial tests a combination of radiation therapy, an immunotherapy drug (tislelizumab), and a targeted therapy drug (anlotinib) for people with liver cancer that has spread into the main vein of the liver. It is for patients who have not had any prior treatment for their liver cancer.
This trial tests a combination of treatments for liver cancer that cannot be removed by surgery. It uses a special radiation therapy called Y90 along with other drugs to see if they work better together.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.